In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eton Pharmaceuticals Inc (ETON), with a price target of $18. The company’s shares closed yesterday at $6.94.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.4% and a 30.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Interpace Diagnostics Group Inc, and Innovate Biopharmaceuticals Inc.
Eton Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $18.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.20 and a one-year low of $5.70. Currently, Eton Pharmaceuticals Inc has an average volume of 59.94K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
